Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
Why Is Sagimet Biosciences Stock Trading Higher On Monday?
Why Sagimet Biosciences Stock Is Soaring Today
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
Sagimet Biosciences Provides Strategic and Corporate Updates
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript
Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?